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Abstract
Background: In 2001, two hexavalent vaccines were licensed in Italy (Hexavac®, Infanrix Hexa®), and since 2002
were extensively used for primary immunization in the first year of life (at 3, 5, 11/12 months of age). In 2005, the
market authorization of Hexavac® was precautionary suspended by EMEA, because of doubts on long-term
protection against hepatitis B virus. The objectives of this study were to evaluate the persistence of antibodies to
anti-HBs, in children in the third year of life, and to investigate the response to a booster dose of hepatitis B
vaccine.
Methods: Participant children were enrolled concomitantly with the offering of anti-polio booster dose, in the
third year of life. Anti-HBs titers were determined on capillary blood samples. A booster dose of hepatitis B
vaccine was administered to children with anti-HBs titers < 10 mIU/ml, with the monovalent precursor product
of the previously received hexavalent vaccine. HBsAb titers were tested again one month after the booster.
Results: Sera from 113 children previously vaccinated with Hexavac®, and from 124 vaccinated with Infanrix
Hexa® were tested for anti-HBs. Titers were ≥ 10 mIU/ml in 69% and 96% (p < 0,0001) respectively. The
proportion of children with titers ≥ 100 mIU/ml did also significantly differ among groups (27% and 78%; p <
0,0001).
Post-booster, 93% of children achieved titers ≥ 10 mIU/ml, with no significant difference by vaccine group.
Discussion: Fifteen months after third dose administration, a significant difference in anti-HBs titers was noted
in the two vaccine groups considered. Monovalent hepatitis B vaccine administration in 3-year old children
induced a proper booster response, confirming that immunologic memory persists in children with anti-HBs titers
< 10 mIU/ml. However, long-term persistence of HBV protection after hexavalent vaccines administration should
be further evaluated over time.
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Background
The hepatitis B vaccine is available since 1982, initially as
a plasma-derived vaccine, and from 1984 onwards as a
recombinant vaccine [1]. Since the late 1990s many com-
bined vaccines which protect against hepatitis B virus
(HBV) and other vaccine-preventable diseases have been
licensed. In particular, in 2001 hexavalent products,
which associate the hepatitis B component to the compo-
nents against diphtheria, poliomyelitis, tetanus, pertussis
and Haemophilus influenzae type b, were introduced in the
European Union.
Currently available vaccines are safe and highly immuno-
genic. In fact, after the administration of three doses of
vaccine, more than 95% of children develop antibodies to
hepatitis B surface antigen (anti-HBs) ≥ 10 mIU/ml, con-
sidered, according to international standards, to be pro-
tective against this infection [1].
The duration of protection induced by plasma-derived
and recombinant vaccines against HBV was investigated
by several authors [2-12], and even if current data show a
decline of antibody titers over time, there is evidence that
immunological memory persists for at least 9–15 years
after immunization [4,7,8,11-13].
On the basis of available data, the European Consensus
Group on Hepatitis B Immunity in 1998 [14], the World
Health Organization in 2002 [15], and the Viral Hepatitis
Prevention Board in 2004 [13] concluded that there is no
evidence to introduce a booster dose in universal hepatitis
B immunization programs.
Recently, a correlation between the antibody titers
observed one month after the administration of the third
hepatitis B vaccine dose, and the long-term persistence of
immunological memory has been shown [3,7,10,11].
Concerns have thus arisen about long-term protection of
children who after vaccination present anti-HBs titers
between 10 and 99 mIU/ml [10], and in 2005, the Euro-
pean Medicines Agency (EMEA) suspended, as a precau-
tionary measure, the marketing authorisation for the
hexavalent vaccine Hexavac® (Sanofi Pasteur MSD) [16].
In fact, it was shown that although more than 95% of chil-
dren vaccinated with Hexavac® developed anti-HBs titers ≥
10 mIU/ml one month after the third dose, 5–20% of vac-
cinees had antibody levels between 10 and 99 mIU/ml.
In Italy, Hexavac®  was licensed in 2001, along with
another hexavalent vaccine (Infanrix Hexa®, SmithKline
Beecham). These two vaccines were extensively used for
primary immunization in the first year of life since August
2002, when the infancy poliomyelitis vaccination sched-
ule was changed, shifting from a sequential scheme with
two doses of live attenuated vaccine (OPV), plus one dose
of inactivated vaccine (IPV), to three doses of IPV. Accord-
ing to this new schedule, infants are vaccinated with three
doses of vaccines against diphtheria, tetanus, HBV, pertus-
sis, polio, and Haemophilus influenzae type b, at 3, 5, 11/12
months of age. In each of the 21 Italian Regions, Local
Health Units are responsible to purchase the vaccines, and
they can choose any product available on the market.
The objective of this study was to evaluate the persistence
of the immune response against hepatitis B virus in chil-
dren vaccinated in the first year of life with a 3-dose course
of available hexavalent vaccines. Children families were
invited to participate when they were actively offered the
polio vaccine booster dose, which, according to Italian
schedule, should be administered in the third year of life.
Methods
Study population
This cohort, prospective study was conducted in two Local
Health Units in Piedmont Region, Northern Italy, from
May 2005 to June 2007.
The two Local Health Units were selected because they
presented a similar organization of vaccination services,
but they used different hexavalent vaccines (Hexavac® and
Infanrix Hexa®).
The planned sample size was 100 children previously vac-
cinated with Hexavac® at 3, 5, 12 months of age, and 100
children who received Infanrix Hexa®  with the same
schedule.
A total sample size of 200 children (100 for group) would
allow for a 92% statistical power to detect a difference of
20% between groups (beta and alfa errors equal to 0.08
and 0.05, respectively).
The inclusion criteria were as follows: a) age between 2
and 3 years; b) vaccination by one year of life (12 ± 2
months of age) with three doses of the same hexavalent
product (Hexavac® or Infanrix Hexa®); c) interval from the
last hexavalent vaccine dose ≥ 12 months.
Children were excluded if they were affected by a chronic
illness, or by a congenital or acquired immune response
disorder.
The study was approved by the ethical committees of the
Local Health Unit in charge of infection disease control in
Piedmont (Alessandria), and of the Italian Institute of
Health (Istituto Superiore di Sanità, Rome). A written,
informed consent was obtained from both parents of each
participant child.BMC Infectious Diseases 2008, 8:100 http://www.biomedcentral.com/1471-2334/8/100
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Evaluation of immunogenicity and response to a booster 
dose
A capillary blood sample was collected at enrollment.
Serum specimens were stored at -20°C, until testing for
anti-HBs antibodies.
Serological testing was carried out at Istituto Superiore di
Sanità. All the serum specimens were tested for quantita-
tive anti-HBs antibodies using a commercial test kit based
on the immunoenzimatic method MEIA (AxSYM AUSAB;
Abbott Laboratories, Abbott Park, IL USA). The test was
used according to the manufacturer's instructions.
Children with anti-HBs titers < 10 mIU/ml were offered a
booster dose with a monovalent hepatitis B vaccine, using
the vaccine produced by the same manufacturer of the
previously administered hexavalent product, i.e.: HBVax-
Pro 5® (Sanofi Pasteur MSD) for children vaccinated with
Hexavac®, and Engerix-B 10® (SmithKline Beecham) for
children vaccinated with Infanrix Hexa®.
A second capillary blood sample was obtained one month
after booster dose administration (30 ± 2 days). The pres-
ence of an anamnestic response was defined as a fourfold
or greater rise in anti-HBs titers between pre- and post-
booster administration, providing that a titer ≥ 10 mIU/
ml was reached after the booster.
After booster administration, parents of participant chil-
dren were also asked to fill-in a 8-day diary, including
information on body temperature and onset of the fol-
lowing signs and symptoms: 1) local reactions (redness,
swelling, pain and itching in the injection site); 2) sys-
temic reactions (sleepiness, irritability, lack of appetite
and vomiting).
Statistical analysis
For each type of vaccine, we estimated the proportion of
participants with anti-HBs titers < 10, 10–99 and ≥ 100
mIU/ml, and the geometric means titers (GMTs) with
95% confidence intervals (95%CI), before and after the
administration of the booster dose.
For the calculation of GMTs, all the sera with anti-HBs tit-
ers ≥ 0.1 were included in the analysis and the highest titer
was fixed to 2000 mIU/ml.
Differences in frequency between groups were compared
with the Chi-square test or Fisher's exact test; t-test or
Mann-Whitney nonparametric test were used to compare
continuous variables.
Relative Risks (RR) with 95% confidence intervals were
calculated. A Poisson multiple regression model with
robust error variance was used to evaluate the role of cov-
ariates.. Variables which differed by study group at the
univariate analysis (p < 0.10) were included into the mul-
tivariate model and retained in the final model according
to a log likelihood ratio test for goodness-of-fit.
Statistical analyses were conducted by using STATA 8.2
(Stata Corporation, College Station, Texas, USA).
Results
Characteristics of participants
A total of 242 participants were enrolled: 113 previously
vaccinated with Hexavac® and 129 with Infanrix Hexa®.
Two participants were excluded from the analysis because
they did not meet the inclusion criteria (i.e., one child
received the third hepatitis B vaccine dose at 15 months of
age; one child received the third dose < one year of enrol-
ment). Additional three samples were not tested because
serum was not sufficient (Figure 1 – Description of study
population).
A total of 237 serum samples were thus analysed: 113 col-
lected from children vaccinated with Hexavac®, and 124
from children vaccinated with Infanrix Hexa®.
The distribution by gender, gestational age, and birth
weight were similar among vaccine groups. By contrast,
mean age, mean interval from third dose, and proportion
of children vaccinated with measles-mumps-rubella vac-
cine (MMR) significantly differed by group (Table 1 –
Characteristics of participants).
Persistence of immunogenicity
Of the 113 children previously vaccinated with Hexavac®,
31% had an anti-HBs titer below the threshold considered
protective, compared with 4% of children of the Infanrix
Hexa® group (p < 0.0001).
The multivariate analysis shows that the type of vaccine
was the only determinant of antibody titer, after adjusting
for age, time-interval from the third hexavalent vaccine
dose, and previous MMR vaccination.
Among the children with a titer ≥ 10 mIU/ml, 60% had a
titer between 10 and 99 mIU/ml in the Hexavac® group,
compared with 18% in the Infanrix Hexa® group (p <
0.0001) (Table 2 – Pre-booster anti-HBs titer by vaccine
group).
Antibody GMTs were also significantly lower in children
vaccinated with Hexavac®, compared to Infanrix Hexa®
[27.6 (95%CI 18.8–40.4) vs 332.2 (95%CI 245.0–450.3)
mIU/ml; p < 0.0001)].BMC Infectious Diseases 2008, 8:100 http://www.biomedcentral.com/1471-2334/8/100
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Response to booster dose
A booster dose of hepatitis B vaccine was administered to
31/40 children with anti-HBs titers < 10 mIU/ml (26 pre-
viously vaccinated with Hexavac®, and 5 with Infanrix
Hexa®).
Of the remaining 9 children, one was lost at follow up,
while the parents of the other 8 declined participation.
One month after the booster vaccination, a second capil-
lary blood sample was obtained from 30 children (Figure
1 – Description of study population).
Two children of the Hexavac® group had a post-booster
anti-HBs titer < 10 mIU/ml; all the other children met the
criteria for the anamnestic response. There was no statisti-
cally significant difference between the two vaccines, in
the proportions of children with a post-booster titer < 10
mIU/ml, and between 10 and 99 mIU/ml (Table 3 – Post-
booster anti-HBs titre by vaccine group).
The only two children who did not respond to the booster
dose were previously vaccinated with Hexavac®, and prior
to the booster had undetectable titers.
Post-booster GMTs did not differ significantly by vaccine
group: 178.0 mIU/ml (95%CI: 87.5–362.3) in children
vaccinated with Hexavac®  vs 124.0 mIU/ml (95%CI:
27.0–568.0) in vaccinated with Infanrix Hexa®  (p =
0.4192).
The diary for recording vaccine side reactions was
returned by 30 participants; parents of 20 children (67%)
recorded at least one event. Fever was described in 13 chil-
dren (43%), being the most commonly reported event. In
most cases (10/13), fever onset was within 3 days of vac-
cination; two of the three children who developed fever
Description of study population Figure 1
Description of study population.
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Table 1: Characteristics of participants
Group 1 Hexavac® Group 2 Infanrix Hexa® p-value
Number 113 124 -
Females, No (%) 44 (38.9) 58 (46.8) 0.2240
Mean age in months (± SD) 26.9 (± 1.2) 26.5 (± 1.3) 0.0232
Mean time in months since the third dose (± SD) 15.8 (± 0.9) 15.3 (± 1.5) 0.0093
Mean birth weight in grams (± SD) 3194.6 (± 560.8) 3233.2 (± 435.3) 0.9116
Mean gestational age in weeks (± SD), 39.3 (± 1.8) 39.2 (± 1.5) 0.4420
Vaccinees with MPR (%) 104 (92.1) 124 (100.0) 0.0010BMC Infectious Diseases 2008, 8:100 http://www.biomedcentral.com/1471-2334/8/100
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after the third day were diagnosed with pharingitis and
influenza. Local reactions were described in 4 participants
(13%).
Discussion
In this study, persistence of HBV immunogenicity was
evaluated in 3-year old children, who are routinely invited
to vaccination services for polio booster administration.
In 2005, these children represented the first cohorts of
individuals who were immunised in infancy with three
doses of hexavalent vaccines.
Our results show a significant difference between the two
products, with lower antibody levels in children previ-
ously vaccinated with Hexavac®, compared to those vacci-
nated with Infanrix Hexa®. In fact, in the Infanrix Hexa®
group the proportion of children with anti-HBs titers < 10
mIU/ml is consistent with the expected proportion of vac-
cine primary nonresponders (about 5%) [1], while it is
eightfold higher among the children vaccinated with Hex-
avac® (31%).
One of the limitations of our study is that anti-HBs titers
after primary immunization are not available, so it is not
known if children with pre-booster titers < 10 mIU/ml
were vaccine primary non-responders or if their titers
declined over time.
Other studies involving children vaccinated with recom-
binant hepatitis B vaccines administered in the first year of
life, found that 36–95% of vaccinees had titers < 10 mIU/
ml, 5–15 years after the primary course [6,8,12,17]. Nev-
ertheless, these data are not directly comparable to our
results, because of two main reasons: 1) these studies were
conducted using monovalent vaccines, and 2) specific
antibody titers were evaluated many years after the com-
pletion of the primary series. By contrast, our data refer to
combined vaccines, and have been obtained shortly after
third dose administration (at a mean interval of 15
months). Therefore, the proportion of individuals with
titers < 10 mIU/ml might increase on a longer evaluation
period.
The higher proportion of children with anti-HBs titers
between 10 and 99 mIU/ml observed in the Hexavac®
group compared to the Infanrix Hexa® group also suggests
a potential further decline of the immunogenicity of this
vaccine over time.
There is no evidence that vaccinated children showing
anti-HBs titers < 10 mIU/ml, measured after more than 30
days from the third dose, are susceptible to HBV infection
[1]. In fact, this value represents a cut-off indicative of
seroprotection when antibodies are tested approximately
30 days after the third dose administration.
When HBV immunogenicity is evaluated at a longer inter-
val from primary vaccination, the presence of specific
immune memory in individuals with anti-HBs titers < 10
mIU/ml can be inferred by testing the response to a
booster dose.
However, there is no standard definition of anamnestic
response to hepatitis B vaccine [4-6,8,10,12,18-20]. Also
the appropriate interval between the booster dose and the
immune response testing is not univocally defined [4-
6,10,17,20], but no appreciable difference has been dem-
onstrated in the anamnestic response evaluated 2 or 4
weeks after booster administration [20]. We thus adopted
the more frequently used definition, that is a fourfold or
greater increase in anti-HBs titer providing that a titer ≥ 10
Table 2: Pre-booster anti-HBs titer by vaccine group.
Anti-HBs titer (mIU/ml) Group 1 (N = 113) Hexavac® n (%) Group 2 (N = 124) Infanrix Hexa® n 
(%)
p-value RR (95%CI)
< 10 35 (31.0) 5 (4.0) < 0.0001* 7.7 (3.1 – 18.9)
10 – 99 47 (41.6) 22 (17.8) < 0.0001** 3.3 (2.1 – 4.9)
≥ 100 31 (27.4) 97 (78.2) - -
* < 10 vs ≥ 10; ** 10–99 vs ≥ 100
Table 3: Post-booster anti-HBs titre by vaccine group.
Anti-HBs titer (mIU/ml) Group 1 (N = 25) Hexavac® n (%) Group 2 (N = 5) Infanrix Hexa® n (%) p-value
< 10 2 (8.0) 0 1.0000*
10–99 4 (16.0) 2 (40.0) 0.2854**
≥ 100 19 (76.0) 3 (60.0) -
* < 10 vs ≥ 10; ** 10–99 vs ≥ 100BMC Infectious Diseases 2008, 8:100 http://www.biomedcentral.com/1471-2334/8/100
Page 6 of 7
(page number not for citation purposes)
mIU/ml is reached [4-6], as measured one month after
booster dose.
According to this definition, 93% of participants mounted
an anamnestic response, in both vaccine groups, and no
differences in post-booster GMTs were evident. This result
is consistent with most of the available literature data,
which show that, 5–13 years after the completion of the
primary course with monovalent recombinant hepatitis B
vaccine, more than 86% of subjects with pre-booster anti-
HBs levels below 10 mIU/ml responded to the booster
vaccination [4,6,8,12,19]. Despite our results are derived
by a limited number of observations, they suggest that
immune memory persists in children previously vacci-
nated with hexavalent vaccines.
Conclusion
Fifteen months after third dose administration, a signifi-
cant difference in anti-HBs titers was noted in the two vac-
cine groups considered. Monovalent hepatitis B vaccine
administration in 3-year old children induced a proper
booster response in both groups, confirming that immu-
nologic memory persists in children with HBsAb titres <
10 mIU/ml.
The administration of anti-poliomyelitis booster was the
first chance to evaluate persistence of memory to HBV
component after vaccination with hexavalent products,
which have been widely used in Italy since 2002. Partici-
pant children were evaluated shortly after completion of
the primary series.
So, cohorts vaccinated with hexavalent products should
be followed to evaluate the trend of anti-HBs titers over
time, in order to determine if immunological memory
persists during adolescence and adulthood. The adminis-
tration of a booster dose targeting adolescents, when the
risk of infection is likely to increase, should be considered
if a decline in immunological memory will be shown.
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